KALA BIO, Inc. (27F0.F)
- Previous Close
2.6120 - Open
2.6940 - Bid 2.6800 x --
- Ask 2.7900 x --
- Day's Range
2.6940 - 2.6940 - 52 Week Range
2.6940 - 10.8500 - Volume
9 - Avg. Volume
1 - Market Cap (intraday)
18.722M - Beta (5Y Monthly) -1.72
- PE Ratio (TTM)
-- - EPS (TTM)
-8.9400 - Earnings Date May 12, 2025 - May 16, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
KALA BIO, Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects. Its preclinical development product, including KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.
www.kalarx.comRecent News: 27F0.F
View MorePerformance Overview: 27F0.F
Trailing total returns as of 4/24/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 27F0.F
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 27F0.F
View MoreValuation Measures
Market Cap
18.15M
Enterprise Value
1.48M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
1.55
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-45.36%
Return on Equity (ttm)
-388.29%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-38.51M
Diluted EPS (ttm)
-8.9400
Balance Sheet and Cash Flow
Total Cash (mrq)
51.18M
Total Debt/Equity (mrq)
261.53%
Levered Free Cash Flow (ttm)
-20.61M